Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EVERLAST: Everolimus + Lenvatinib versus Everolimus for progressive bone sarcoma
KCT0012001Phase 2Not yet recruiting
- Sponsor
- Boryung
- Start
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in bone cancer and Primary bone malignancy (None.) comparing Everolimus + Lenvatinib with Everolimus (2 arms). Planned start Jul 2026; status: not yet recruiting.
02
Drugs
everolimuslenvatinib
03
Conditions
bone cancerPrimary bone malignancy (None.)
Beyond the preview
Go deeper on KCT0012001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0012001.